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Background: To date, no prognostic microRNAs (miRNAs) for isocitrate dehydrogenase 1 (IDH1) wild-type
glioblastoma multiformes (GBM) have been reported. The aim of the present study was to identify a miRNA
signature of prognostic value for IDH1 wild-type GBM patients using miRNA expression dataset from the The
Cancer Genome Atlas (TCGA).
Methods: Differential expression profiling analysis of miRNAs was performed on samples from 187 GBM patients,
comprising 17 mutant-type IDH1 and 170 wild-type IDH1 samples.
Results: A 23-micoRNA signature which was specific to the IDH1 mutation was revealed. Survival data was available for
140 of the GBM patients with wild-type IDH1. Using these data, the samples were characterized as high-risk or low-risk
group according to the ranked protective scores for each of the 23 miRNAs in the 23-miRNA signature. Then, the 23 IDH1
mutation-specific miRNAs were classified as risky group and protective group miRNAs based on the significance analysis of
microarrays d-score (SAM d-value) (positive value or negative value). The risky group miRNAs were found to be expressed
more in the high-risk samples while the protective group miRNAs were expressed more in the low-risk samples. Patients
with high protective scores had longer survival times than those with low protective scores.
Conclusion: These findings show that IDH1 mutation-specific miRNA signature is a marker for favorable prognosis in
primary GBM patients with the IDH1 wild type.
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MicroRNAs (miRNAs) are short noncoding ribonucleic
acid (RNA) molecules, approximately 22-nucleotide long,
and single-stranded [1]. MiRNAs are post-transcriptional
regulators that bind to complementary sequences on target
messenger RNA transcripts (mRNAs), usually resulting in
translational repression or target degradation and gene si-
lencing, thereby modulating a variety of biological process* Correspondence: Gujun_2013@163.com; zhangwei_vincent@126.com
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reproduction in any medium, provided the orsuch as cell growth, proliferation, differentiation, metabo-
lism, and apoptosis [2-4]. Some miRNAs are reported to be
associated with clinical outcomes in some tumors, such as
blood carcinomas [5,6], lung cancer [7,8], pancreatic cancer
[9,10], and colon adenocarcinoma [11,12].
Glioblastoma (GBM, WHO grade IV glioma) is the most
malignant brain tumor in adults. Even after treatment with
surgical resection and radiotherapy plus concomitant chemo-
therapy, most patients with the diagnosis of GBM seldom
survive more than 15 months [13]. A number of molecular
markers for GBM associated with diagnosis, prognosis, and
treatment have been identified. Somatic mutations in IDH1
have been identified in GBM patients, especially in secondary
GBM which evolves from lower-grade gliomas [14]. Several
miRNA signatures associated with IDH1 mutations havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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outcomes have been predicted for GBM patients with
IDH1 mutations [1]. However, to date, no valuable prog-
nostic miRNA signatures have been reported for patients
with wild-type IDH1 GBM. In the present study, we
used the GBM miRNA dataset from The Cancer
Genome Atlas (TCGA, http://cancergenome.nih.gov/) and
selected miRNAs that were differentially expressed
between wild-type and mutant-type IDH1 GBM sam-
ples. As a result, we successfully identified a 23-miRNA
signature, which predicted a better outcome for GBM
patients with wild-type IDH1.
Methods and materials
Samples
MiRNA expression data (level 3) and the corresponding
survival data for glioblastoma samples were downloaded
from The Cancer Genome Atlas (TCGA) data portal. Two
mutant-type IDH1 samples and 30 wild-type IDH1 sam-
ples were removed during analysis because of unavailable
survival information or very short survival time (less than
30 days, probably caused by other lethal factors). Thus, a
total of 155 GBM patients, with 15 mutant-type and 140
wild-type IDH1 patients, were enrolled for further ana-
lysis. Because the data were obtained from TCGA, further
approval by an ethics committee was not required.
Whole-genome microRNA profiles of glioblastoma pa-
tient were downloaded from public the Cancer Genome
Atlas (TCGA) database (http://cancergenome.nih.gov/).
Data analysis
Differential expression profiling analysis was performed on
the GBM miRNA dataset of TCGA using significanceFigure 1 The IDH1 mutation-specific 23-miRNA signature. The 23 miRN
samples with mutant-type IDH1 compared to those with wild-type IDH1.analysis of microarrays (SAM), performed using BRB-
ArrayTools developed by Dr. Richard Simon and the BRB-
ArrayTools Development Team (available at http://linus.
nci.nih.gov/BRB-ArrayTools.html). The differential expres-
sion standard was set to 1.5 fold (SAM-d value score
greater than 1.5 or less than −1.5) and P-values less than
0.01 were taken as significant. The SAM application calcu-
lates a score for each miRNA on the basis of the change of
expression relative to the standard deviation of all mea-
surements. To assess the survival prediction value of se-
lected miRNAs, a protective-score formula for predicting
survival was developed based on a linear combination of
the miRNA expression level multiplied by the SAM d-
value. MiRNAs from 155 GBM patients, including 15
mutant-type and 140 wild-type IDH1 samples, that
showed enormous differences in expression between the
wild-type and mutant-type IDH1 GBM samples, were se-
lected for further analysis.
Results
Identification of the 23-miRNA signature
Twenty-three miRNAs were identified from the total of
470 GBM miRNAs in TCGA and defined as IDH1
mutation-specific miRNA signatures (Figure 1). Each of
the 23 miRNAs showed significantly aberrant expression
in the mutant-type IDH1 samples and, thus, were defined
as a 23-miRNA signature specific to IDH1 mutation.
Accessing protective scores
To assess the value of survival prediction for the 23-
miRNA signature protective-scores were calculated for all
enrolled GBM patients. The 140 patients with wild-type
IDH1 were ranked according to the protective score valuesAs were differentially expressed by more than 1.5 fold in GBM
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survival data (Figure 2B and 2C). Using the 60th percent-
ile protective-score as a cutoff, the 140 wild-type IDH1
samples were divided into two groups, high-risk (corre-
sponding to the low-score group) and low-risk group (cor-
responding to the high-score group) (Figure 2A and 2C).
The 23 miRNAs were divided into two groups ac-
cording to the SAM d-value (positive value or negative
value), the risky group and the protective group with 16
and seven miRNAs, respectively (Figure 2C). Protective
miRNAs were expressed at higher levels in the low-risk
group, while risky miRNAs tended to be expressed more
in the high-risk group (Figure 2C).
We also compared the overall survival of the patients
in the mutant-type (15 samples) and the wild-type IDH1
groups (140 samples) and found statistically significant
differences between them (Figure 3A, P = 0.0001). Kaplan-
Meier curves for the low-score and high-score groups
were shown in Figure 3B. A statistically significant differ-
ence was observed between the two groups (P = 0.0045).Figure 2 Protective scores for the 23-miRNA signature and survival d
scores. B. Survival days for the 140 GBM patients. C. The risky group and p
in the high-risk group and protective miRNAs were expressed more in thePatients in the high-score group had better outcomes than
patients in the low-score group. Thus, the 23-miRNA sig-
nature, which was specific to IDH1 mutation in the GBM
samples, may be a marker of favorable prognosis in wild-
type IDH1 GBM patients.
Discussion
Primary GBM is considered to be the most lethal brain
tumor in adults. The prognosis is variable, with some
patients surviving less than a year and others surviving
for three years or more [13]. To date, only IDH1 mu-
tation and O-6-methylguanine-DNA methyltransferase
(MGMT) promoter methylation have been identified as
stable prognostic indicators for GBM patients across
various studies. IDH1 mutations were reported to have a
strong positive correlation with overall survival in sec-
ondary and primary GBMs, although the mutation rate
in primary GBM was much lower than that in secondary
GBM [14]. Through differential miRNA expression pro-
filing, we identified a 23-miRNA signature that wasays in GBM patients with wild-type IDH1. A. Ranked protective
rotective group for the 23 miRNAs. Risky miRNAs were expressed more
low-risk group.
Figure 3 Overall survival of GBM patients in the mutant-type and wild-type IDH1 groups. A. Patients with mutant-type IDH1 had much
better outcome than those with wild-type IDH1. B. Kaplan-Meier curves for the low-score and high-score groups. In the 140 IDH1 wild-type GBM
patients, patients in the high-score group had much longer overall survival times than those in the low-score group.
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mutant-type IDH1. Nevertheless, until now, no miRNA
signature that could serve as an indicator for GBM in
patients with IDH1 wild-type is available.
Here, we used a scoring method to measure the relative
expression levels of the 23 miRNAs. Then we divided all
of the samples into high-score and low-score groups as
shown in Figure 2. We found that the high-score group
had better clinical outcomes than the low-score group.
According to the SAM-d value, these miRNAs were de-
fined as risky miRNA group and protective miRNA group.
Seven miRNAs were designated as risky miRNAs, of
which higher expressions indicated worse outcomes, and
16 miRNAs were designated protective miRNAs, of which
higher expressions indicated better outcomes for GBM
patients.
A recent study, which examined the expression data of
305 miRNAs from 222 GBM samples in TCGA dataset,
identified a 10-miRNA prognostic signature [15]. The
10-miRNA signature is partially consistent with the 23-
miRNA signature that we identified in the present study.
The two signatures share six miRNAs, including are
protective miRNAs (miR-20a, miR-106a, miR-17-5p) and
three risky miRNAs (miR-221, miR-222, miR-148a). To
some extent, the overlap between the two miRNA signa-
tures verified the potentially clinically predictive signifi-
cance of, at least, the 6-miRNA signature. A possible
explanation for why the two signatures did not agree
exactly may be because of differences in the target popula-
tion and/or the entry criteria. In another study, a 5-miRNA
signature was identified as a prognostic biomarker in
Chinese patients with primary GBM [1]. This 5-miRNA
signature (miR-181d, miR-518b, miR-524-5p, miR-566, and
miR-1227) was significantly associated with improved over-
all survival for GBM patients. Interestingly, none of the five
miRNAs in this signature overlapped with the miRNAs in
our 23-miRNA signature, probably because different pa-
tient populations and datasets were used in the two studies.We further investigated the six miRNAs that were com-
mon to the 10-miRNA and 23-miRNA signatures. Some
studies have shown that miR-183 was significantly down-
regulated in osteosarcoma and may subsequently promote
migration, invasion, and recurrence of osteosarcoma [16].
In our study, we found that miR-183 was a favorable
predictor for GBM, which was consistent with its effect in
osteosarcoma. In advanced colorectal cancer, miR-148a
expression was the most significantly downregulated,
which resulted in a worse therapeutic response and poor
overall survival [17]. A similar effect was found in GBM,
and, in our study, miR-148a was classified as one of the
risky biomarkers for GBM. In a study of adult T-cell
leukemia, miR-155 was identified as a novel unfavorable
biomarker for disease progression and prognosis [18]. An-
other study reported that elevation of plasma miR-155
was associated with shorter survival times in non-small
cell lung cancer [19]. These findings were consistent with
our results for the function of miR-155. MiR-221 and its
paralogue miR-222 are known inhibitors of angiogenesis,
which act by blocking cell migration and proliferation in
endothelial cells [20,21]. Other studies have reported dif-
ferent functions for miR-221, suggesting that miR-221 was
also associated with induction of angiogenesis [22,23]. In
our research, miR-221 and miR-222 were identified as
unfavorable indictors for GBM. In a study into chronic
lymphocytic leukemia, miR-34a and miR-17-5p were
found to be downregulated in chronic lymphocytic leu-
kemia patients with tumor protein p53 (TP53) abnormal-
ities, indicating that higher expression levels of miR-34a
and miR-17-5p may predict a better clinical outcome for
these patients [24].
In TCGA, the IDH1 mutation-type samples account for
only 10–16% of the GBMs, most of which are secondary
GBMs. Our results provided a robust clinical prognostic
indicator for GBM patients with wild-type IDH1. How-
ever, we still have no idea how exactly this 23-miRNA sig-
nature worked in GBM. Clearly, the mechanisms behind
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Better insights into how the 23-miRNA signature func-
tions in GBM will potentially contribute to an understand-
ing of the genetic aberrations that are involved in tumor
genesis, progression, and/or response to treatment. In
particular, there are a number of significant advantages
over microarray methodologies for the routine examin-
ation of miRNA signatures. Analysis can be undertaken
straightforwardly, rapidly and cost-effectively. It is much
more applicable and feasible to be tested in the clinical
practice than whole genome miRNA profiling. Further-
more, these profoundly aberrantly expressed miRNAs
can serve as potential molecular targets for new thera-
peutic strategies, subsequently leading to improved out-
comes for GBM patients.
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